American Society of Hirudotherapy

A case of leech-associated infection involving an extended-spectrum β-lactamase-producing and extensively drug-resistant Aeromonas isolate

Case report published in Clinical Microbiology and Infection (2018)

Last Updated: November 1, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportSafety & Infection ControlFloug Q et al. · Clinical microbiology and infection, 2019

Summary

Reports first leech-therapy infection caused by an extensively drug-resistant Aeromonas producing ESBL — sensitive only to colistin and tigecycline.

Citation

Reference (Vancouver style)

Floug Q, Sinna R, Fillatre A, Plésiat P, Hamdad F. A case of leech-associated infection involving an extended-spectrum β-lactamase-producing and extensively drug-resistant Aeromonas isolate. Clin Microbiol Infect. 2019;25(3):394-395. doi:10.1016/j.cmi.2018.11.006. PMID: 30472419

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

DOIPubMed

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.